BiotechTube

Hib-CRM197 + Hib-TT

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Meningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type b

Conditions

Meningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type b

Trial Timeline

Nov 1, 2014 → Jan 1, 2015

NCT ID
NCT02139228

About Hib-CRM197 + Hib-TT

Hib-CRM197 + Hib-TT is a phase 3 stage product being developed by Novartis for Meningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type b. The current trial status is completed. This product is registered under clinical trial identifier NCT02139228. Target conditions include Meningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type b.

What happened to similar drugs?

8 of 20 similar drugs in Meningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type b were approved

Approved (8) Terminated (0) Active (12)
✅Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine + MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus VaccineNovartisApproved
✅4CMenBNovartisApproved
✅Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate + Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate + Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid ConjugateSanofiApproved
✅Meningococcal polysaccharide diphtheria toxoid conjugate + Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b ConjugateSanofiApproved
✅T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj. + Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj. + Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dapSanofiApproved
✅Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid ConjugateSanofiApproved
✅Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate VaccineSanofiApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02139228Phase 3Completed

Competing Products

20 competing products in Meningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type b

See all competitors
ProductCompanyStageHype Score
RotaTeq® + NeisVac-C®MerckPhase 3
40
DaptomycinMerckPre-clinical
18
Meningococcal ACWY conjugate vaccineNovartisPhase 3
40
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine + MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus VaccineNovartisApproved
43
Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaPNovartisPhase 3
40
Meningococcal (Groups A, C, Y and W-135) Conjugate + Meningococcal polysaccharide A, C, Y and W135 and MenveoNovartisPhase 3
40
Meningococcal ACWY conjugate vaccineNovartisPhase 3
40
MenACWY-CRM + MenC-CRM + DTaP-Hib-IPV + PC7 + MMR + VaricellaNovartisPhase 2
35
Novartis Meningococcal ACWY Conjugate Vaccine + Tdap Vaccine + Novartis Meningococcal ACWY Conjugate VaccineNovartisPhase 3
40
MenACWY-CRM conjugate vaccine, adjuvanted + MenACWY polysaccharide vaccine + MenACWY-CRM conjugate vaccine, unadjuvantedNovartisPhase 2
35
meningococcal B vaccine & meningococcal ACYW conjugate vaccineNovartisPhase 2
35
Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosineNovartisPhase 2
27
4CMenBNovartisApproved
43
Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccineNovartisPhase 3
40
Meningococcal (group B) multicomponent recombinant adsorbed vaccineNovartisPhase 3
40
MenACWY-CRM197 (two doses) + MenC + PCV7 + DTPa-IPV-HepB-Hib + MenACWY-CRM197 (one dose)NovartisPhase 3
40
MenACWY-CRM197 + DTaP (Diptheria, Tetanus, Pertussis) Vaccine + Hib (Haemophilus influenza b) Vaccine + IPV (Inactivated Polio Vaccine) Vaccine + Pneumococcal conjugate Vaccine + MMR (Measles, Mumps, and Rubella) Vaccine + Varicella Vaccine + Hepatitis A VirusNovartisPhase 3
40
Meningococcal ACWY Polysaccharide Vaccine + MenACWY CRM (19 to 55 years) + Meningococcal ACWY Conjugate Vaccine + Novartis MenACWY Vaccine (56 to 65 Years)NovartisPhase 3
40
Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Control + Meningococcal B vaccine with antipyreticNovartisPhase 2
35
Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1) + Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2) + Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3) + Infanrix Hexa + Menjugate + PrevenarNovartisPhase 3
40